Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05647083
Other study ID # BAIBU-SBF-EGS-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2022
Est. completion date February 9, 2024

Study information

Verified date April 2024
Source Abant Izzet Baysal University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research aims to investigate the effect of massage on diabetic foot risk, HbA1c and physiological parameters in individuals with type 2 diabetes. This randomized controlled experimental design will be carried out in Bolu Izzet Baysal State Hospital Köroğlu Unit Internal Medicine Polyclinic and Internal Medicine Service. According to power analysis, the minimum sample size was determined as 60 people, 30 of which were in the intervention group and 30 in the control group. Data collection tools include "Peripheral Neuropathy Sign and Symptom Score", "Ankle-Brachial Index (ABI)", "Glycemic Control Assessment (HbA1c)", "Physiological Parameters (blood pressure, heart rate and oxygen saturation)", "Inlow's 60-second Diabetic Food Screen". A total of 24 massage sessions will be applied to the intervention group, 2 times a week during the 12-week working period. Participants in the control group will continue their medical treatment protocols and massage will not be applied.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date February 9, 2024
Est. primary completion date February 9, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria: - Being between 30-75 years old, - Diagnosed with diabetes at least 6 months ago, - Absence of irritation, ulceration in the areas where the massage will be applied (hands, feet and legs), - No problem in verbal communication, - Being able to speak Turkish, - No diagnosis of psychiatric disease, - Absence of amputation in the upper and lower extremities, - Having HbA1c test results in the last 1 week, - Not having had Covid-19 in the last 6 months - No experience of massage application in the last 1 month - Willingness to participate in the research Exclusion Criteria: - Presence of diabetic ulcer and foot wound, - Irritation and ulceration in the areas where the massage will be applied (hands, feet and legs), - Having problems in verbal communication, - Not being able to speak Turkish, - Having a diagnosis of psychiatric illness.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Massage therapy
Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.

Locations

Country Name City State
Turkey Bolu Provincial Health Directorate Bolu Izzet Baysal State Hospital Bolu

Sponsors (1)

Lead Sponsor Collaborator
Abant Izzet Baysal University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Means of Peripheral Neuropathy Sign and Symptom Score Peripheral neuropathy consists of two parts: symptom and symptom score. For the peripheral neuropathy symptom score;
Discomfort they feel in their feet,
Location of complaints,
The presence of complaints increases at night,
Time of occurrence of complaints and
5 questions will be asked about how the complaints decreased. Peripheral neuropathy symptom score obtained from 5 questions was 0-2 points, "normal"; 3-4 points, "mild neuropathy"; 5-6 points, "moderate neuropathy"; A score of 7-9 will be considered "severe neuropathy".
For peripheral neuropathy finding score; It will be determined based on four parameters including 1. Vibration sense, 2. Pimpiric test, 3. Achille tendon reflex, 4. Protective sensory examination
Change from baseline Neuropathy score at 3 months
Primary Means of Ankle-Brachial Index Score It is calculated by dividing the tibialis posterior pressure by the brachial arterial pressure. The highest of the four measurements at the ankles and feet is divided by the two higher brachial measurements. The normal value is close to 1. Change from baseline Ankle-Brachial Index score at 3 months
Primary Means of HbA1c (%) HbA1c values of the participants will be monitored as a glycemic control parameter. The HbA1c value will be evaluated at baseline and 3 months later, as it represents the three-month average blood glucose value. For the measurement of HbA1c, the test results within the last week will be taken from the participants at the beginning and a blood sample will be taken into ethylenediaminetetraacetic acid (EDTA) coated tubes (2 mL whole) by a nurse three months later. Change from baseline HbA1c score at 3 months
Primary Means of systolic blood pressure (mmHg) It will be measured by the researcher with a manual measurement tool. Change from baseline systolic blood pressure at 3 months
Primary Means of diastolic blood pressure (mmHg) It will be measured by the researcher with a manual measurement tool. Change from baseline diastolic blood pressure at 3 months
Primary Means of heart rate (/minutes) It will be measured by the researcher with a pulse oximeter. Change from baseline heart rate at 3 months
Primary Means of oxygen saturation (%) It will be measured by the researcher with a pulse oximeter. Change from baseline oxygen saturation at 3 months
Primary Means of diabetic foot risk score "Inlow's 60-second Diabetic Food Screen" form will be used in diabetes foot risk assessment. Diabetic foot examination consists of 12 parameters. Skin Assessment, Evaluation of Nail Structure, deformity, Evaluation of the Shoe, Heat Evaluation - Being Cold, Heat Evaluation - Being Hot, Range of Motion Evaluation, Sensory Evaluation, Sensory Evaluation (Assessment with questions directed to individuals), Evaluation of Pedal Pulses, Dependent Rubor Evaluation, Evaluation of Erythema (Redness). The minimum score to be taken from the foot examination form is evaluated as 0 and the maximum score as 23 points. The higher the score, the higher the risk of diabetic foot. Change from baseline diabetic foot risk score at 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2
Completed NCT02897349 - Linagliptin Add-on to Insulin Background Therapy Phase 3